These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Cholecystokinin-octapeptide effects on conditioned-avoidance behavior, stereotypy and catalepsy. Cohen SL; Knight M; Tamminga CA; Chase TN Eur J Pharmacol; 1982 Sep; 83(3-4):213-22. PubMed ID: 6129145 [TBL] [Abstract][Full Text] [Related]
7. Effects of cholecystokinin octapeptide on striatal dopamine metabolism and on apomorphine-induced stereotyped cage-climbing in mice. Kovács GL; Szabó G; Penke B; Telegdy G Eur J Pharmacol; 1981 Jan; 69(3):313-9. PubMed ID: 6260512 [TBL] [Abstract][Full Text] [Related]
8. Effects of sulfated cholecystokinin octapeptide and cholecystokinin tetrapeptide in rat behavior after blockade of nitric oxide synthase by L-NAME. Hoły Z; Wiśniewski K Rocz Akad Med Bialymst; 1998; 43():250-70. PubMed ID: 9972062 [TBL] [Abstract][Full Text] [Related]
9. Mixed D2/5-HT2 antagonism differentially affects apomorphine- and amphetamine-induced stereotyped behavior. Feldman DJ; Frank RA; Kehne JH; Flannery R; Brown D; Soni S; Byrd G; Shah S Pharmacol Biochem Behav; 1997 Oct; 58(2):565-72. PubMed ID: 9300620 [TBL] [Abstract][Full Text] [Related]
10. Effects of cholecystokinin on apomorphine-induced changes of motility in rats. Katsuura G; Itoh S; Rehfeld JF Neuropharmacology; 1984 Jul; 23(7A):731-4. PubMed ID: 6089021 [TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin [corrected] octapeptide modulates dopamine release in rat striatum. Rakovska A Neurosci Lett; 1995 Aug; 195(3):151-4. PubMed ID: 8584197 [TBL] [Abstract][Full Text] [Related]
13. Evidence for dopaminomimetic effect of intrastriatally injected cholecystokinin octapeptide in mice. Worms P; Martinez J; Briet C; Castro B; Biziere K Eur J Pharmacol; 1986 Mar; 121(3):395-401. PubMed ID: 3699101 [TBL] [Abstract][Full Text] [Related]
14. Cholecystokinin potentiates dopamine-mediated behaviors: evidence for modulation specific to a site of coexistence. Crawley JN; Stivers JA; Blumstein LK; Paul SM J Neurosci; 1985 Aug; 5(8):1972-83. PubMed ID: 4040554 [TBL] [Abstract][Full Text] [Related]
15. Brain CCK-B receptors mediate the suppression of dopamine release by cholecystokinin. Altar CA; Boyar WC Brain Res; 1989 Apr; 483(2):321-6. PubMed ID: 2706523 [TBL] [Abstract][Full Text] [Related]
16. Neurotensin and cholecystokinin octapeptide control synergistically dopamine release and dopamine D2 receptor affinity in rat neostriatum. Tanganelli S; Li XM; Ferraro L; Von Euler G; O'Connor WT; Bianchi C; Beani L; Fuxe K Eur J Pharmacol; 1993 Jan; 230(2):159-66. PubMed ID: 8422898 [TBL] [Abstract][Full Text] [Related]
17. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway. Crawley JH Prog Clin Biol Res; 1985; 192():131-8. PubMed ID: 4080706 [TBL] [Abstract][Full Text] [Related]
18. Effect of naloxone and morphine on dopamine agonist-induced stereotypy in rats and guinea pigs. Feigenbaum J; Yanai J; Moon B; Klawans H Neuropharmacology; 1983 Dec; 22(12A):1369-76. PubMed ID: 6686653 [TBL] [Abstract][Full Text] [Related]
20. Reversal by cholecystokinin of apomorphine-induced inhibition of dopamine release in the nucleus accumbens of the rat. Blaha CD; Phillips AG; Lane RF Regul Pept; 1987 Jun; 17(6):301-10. PubMed ID: 3602473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]